NEW DELHI: All India Institute of Medical Sciences (AIIMS) in Patna on Wednesday began clinical trials of the indigenous Covaxin for children in the age group of 2 to 18 years, according to Prasar Bharati.
Registration for the children to participate in the second phase clinical trial of the Covid-19 vaccine was made open from last week at AIIMS-Patna.
The move came after the Drugs Controller General of India (DGCI) granted permission for the phase 2-3 clinical trial of Covaxin on children. AIIMS-Patna has been selected as one of the sites for the trial along with other institutes such as AIIMS-Delhi and Meditrina Institute of Medical Sciences, Nagpur.
As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the medicine in India, Sun Pharma said.
The indigenous Covid-19 drug developed by the Defence Research and Development Organisation (DRDO) is not connected with research done by Patanjali Ayurved, contrary to the claims made by the Swami Ramdev-promoted company.
India News: NEW DELHI: Defence Research and Development Organisation's (DRDO) anti-Covid-19 drug will be sold at Rs 990 per sachet by Dr Reddy's Laboratories (DRL.
In a strongly worded letter to Ramdev, the minister also said that "through your statement you not only disrespected corona warriors but also deeply hurt the sentiments of countrymen".